Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.Appropriate studies have not been performed on the relationship of age to the effects of lubiprostone in the pediatric population. The forward-looking statements in this press release are qualified by these risk factors. Investors should note that many factors, as more fully described under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval and as otherwise enumerated herein or therein, could individually or in the aggregate affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in the forward-looking statements or from historical results. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Holden and other statements regarding reliability, quality, product potential, availability and affordability. ![]() This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation, including the statements by Mr. Par is advancing a robust development pipeline of potential products. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and other differentiated products. Par Pharmaceutical develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical and branded injectable products that help improve patient quality of life. Learn more at or connect with us on LinkedIn. ![]() Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. "Par is proud to be a reliable, quality supplier that can help bring that choice to patients while expanding our product portfolio."Īccording to IQVIA ™, Amitiza ® capsule sales were approximately $427 million for the 12 months ended September 30, 2020.Īmitiza® is a registered trademark of a Mallinckrodt company.Įndo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. "This partnership brings the first Amitiza ® generic to patients-giving them a cost-effective alternative," said Jon Holden, Senior Vice President and General Manager, Generics at Endo. ![]() (Par), has begun shipping the first authorized generic versions of Mallinckrodt's Amitiza ® (lubiprostone) 8 mcg and 24 mcg capsules. 4, 2021 /CNW/ - Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |